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A b s t r a c t
Background: Cardiac resynchronisation therapy (CRT) has been shown to reduce functional mitral regurgitation, although the 
relationship between significant mitral regurgitation (SMR) and the clinical prognosis of CRT remains uncertain.
Aim: We sought to investigate the association of baseline SMR with long-term outcomes in patients undergoing CRT.
Methods: A total of 296 consecutive patients undergoing CRT were enrolled. SMR was quantified by colour Doppler in all 
patients at baseline and defined as level ≥ 3 on the severity scale. The primary endpoints included all-cause death, heart 
failure hospitalisation (HFH), and heart transplantation, and the secondary endpoints were response to CRT and New York 
Heart Association (NYHA) class III or IV six months after CRT implantation. 
Results: The mean age was 59 ± 11 years, and 202 (68.2%) patients were male. Among all patients, 124 (41.9%) presented 
with baseline SMR. Over a mean follow-up of 4.17 ± 3.16 years, there were 53 (17.9%) cases of all-cause death, 41 (13.8%) 
cases of HFH, and four (1.4%) cases of heart transplantation. SMR was positively associated with primary endpoint events 
(hazard ratio [HR] 1.602, 95% confidence interval [CI] 1.083–2.371, p = 0.019), HFH (HR 3.567, 95% CI 1.763–7.219, 
p < 0.001) and NYHA class III or IV (HR 2.101, 95% CI 1.313–3.363, p = 0.002). After adjusting for multiple factors, we 
found that SMR (HR 1.785, 95% CI 1.091–2.920, p = 0.021), ischaemic heart disease (HR 1.628, 95% CI 1.062–2.494, 
p = 0.025), and the lack of use of spironolactone (HR 2.044, 95% CI 1.040–4.017, p = 0.038) were independent predictors 
of primary endpoints, and SMR remained an independent predictor of HFH (HR 4.622, 95% CI 1.955–10.923, p < 0.001). 
Conclusions: Significant mitral regurgitation before CRT implantation was strongly associated with long-term poor progno-
sis. SMR was positively associated with HFH rather than all-cause death and CRT response.
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INTRODUCTION
Heart failure (HF) is a progressive disease with high morbidity 
and prevalence [1]. Functional mitral regurgitation (FMR) is 
the most common valvular heart disorder among HF patients 
[2, 3]. A quarter of hospitalised patients with HF present at 
least a minimal amount of significant mitral regurgitation 
(SMR), and more than half of them suffer from moderate to 
severe FMR at baseline [4, 5]. Left ventricular remodelling and 
ventricular systolic dyssynchrony have been shown to be the 
pathophysiological processes in HF patients with FMR [6]. 
Cardiac resynchronisation therapy (CRT) improves life qual-
ity and survival rate among advanced HF patients with ventricular 
dyssynchrony [7, 8]. It has been shown that CRT efficiently re-
duces SMR in HF patients [9–11]. However, whether SMR can 
effectively predict the long-term quality of life and mortality in 
CRT candidates remains inconclusive and requires further study.
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METHODS
A total of 316 consecutive participants with CRT pacemaker 
(CRT-P) or defibrillator (CRT-D) were enrolled in our study 
from March 2001 to January 2016 in the Arrhythmia Centre 
of Fuwai Hospital. Inclusion criteria were in accordance with 
guidelines for CRT-P/D implantation [12]. Before device 
implantation, all patients had already been on maximum 
optimal medical therapy for at least three months. Seven 
patients were excluded due to age < 18 years old, primary 
mitral regurgitation, or pregnancy. Thirteen patients were lost 
during the follow-up period. Overall, a total of 296 patients 
were enrolled. Ischaemic heart disease (IHD) was defined as 
cardiomyopathy with impaired contractile performance and 
a history of myocardial infarction. Intervention treatments 
included percutaneous coronary intervention, coronary artery 
bypass grafting, or clear evidence of coronary stenosis (more 
than 75%) [13].
The study was approved by the Institutional Review Board 
of Fuwai Hospital and complied with the Declaration of Hel-
sinki. Informed consent was obtained from all participants.
Device therapy
Technical aspects of lead and device implantation are briefly 
described. The coronary sinus was cannulated from the left 
subclavian and/or cephalic entry site using a commercially 
available long, peelable guiding sheath. The left ventricular 
(LV) lead was positioned preferably in the lateral or postero-
lateral vein. The right atrial and right ventricular (RV) leads 
were placed regularly at the right atrial appendage and the 
RV apex, respectively. For patients with permanent atrial 
fibrillation, only RV and LV leads were implanted, plugging 
the atrial port and programming the generator to a ventricu-
lar-triggered mode. Ablation of atrioventricular junction was 
not performed in any patient. All procedures were performed 
under local anaesthesia.
Echocardiography, biochemistry, and programming
Fasting venous blood samples and the test results of N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) were collected 
from each patient on the day before CRT device implanta-
tion. Two independent certificated sonographers performed 
two-dimensional echocardiography (Vivid 7 Dimension/Pro 
System, GE Healthcare, Chalfont St. Giles, Bucks, UK) to 
assess the level of FMR, LV end-systolic diameter (LVESD), 
LV end-diastolic diameter (LVEDD), LV end-systolic volume 
(LVESV), and LV ejection fraction (LVEF) according to modified 
Simpson’s rule on the day before device implantation. The 
severity of FMR was classified into four levels: mild — grade 1 
(jet area/left atrial area < 20%), moderate — grade 2 (jet 
area/left atrial area 20%–30%), moderately severe — grade 3 
(jet area/left atrial area 30%–40%), and severe — grade 4 
(jet area/left atrial area > 40%) [14]. SMR was defined as 
level ≥ 3 according to colour Doppler in all the patients at 
baseline. 
For optimisation, patients in sinus rhythm underwent 
transmitral Doppler-derived optimisation of atrioventricular 
delay using an iterative technique [15] prior to discharge and 
at every scheduled visit thereafter. V-V delay ranged from 0 to 
40 ms, according to the standard of the shortest biventricular 
paced QRS duration. 
Follow-up and assessment of endpoints
Baseline electrocardiography and clinical assessment were col-
lected via Hospital Information System. All patients underwent 
regular follow-up via outpatient clinical visits or telephone 
interviews. Physicians from Fuwai Hospital assessed the 
events. All the physicians were blinded to the results of FMR 
levels and patients’ clinical data, and independently judged 
the clinical events.
Primary endpoints were all-cause death, heart trans-
plantation, and HF hospitalisation (HFH). If episodes of HFH 
occurred more than once, only the first hospitalisation was 
recorded. 
Secondary endpoints included: response to CRT and New 
York Heart Association (NYHA) functional class III or IV six 
months after CRT implantation; response to CRT was defined 
as > 15% decrease of LVESV after six months [16]. Patients 
who died or underwent heart transplantation within six 
months after implantation were regarded as non-responders.
Statistical analysis
All data were processed using SPSS 22.0 (SPSS Inc., Chi-
cago, IL, USA). Continuous variables were presented as 
mean ± standard deviation (SD) and compared using the 
independent samples t test. Categorical data were summarised 
as frequencies and percentages and were compared using 
the c2 test. The Kaplan-Meier method with log-rank test was 
used to analyse the survival of patients free from endpoint 
events. Univariable binary logistic and Cox regression analyses 
were used to determine predictors of the primary and second-
ary endpoints, respectively. Multivariate regression analysis 
with stepwise selection method was performed to control 
potentially confounding demographic, echocardiographic and 




The participants were divided into an SMR group and 
a non-SMR group. The mean age of study cohort was 
59 ± 11 years. Of the enlisted patients, 202 (68.2%) were 
male, 43 (14.5%) had atrial fibrillation, 251 (84.8%) had 
left bundle branch block, 143 (48.3%) had CRT-D, and 
63 (21.3%) patients had IHD. Overall, 69 (23.3%) patients 
were NYHA class II, 174 (58.8%) were NYHA class III, 
and 50 (16.9%) were NYHA class IV. The mean LVEDD 
was 70.39 ± 9.40 mm, LVESD was 60.43 ± 24.96 mm, 
and LVEF was 29.02% ± 7.88%. Patients in the SMR 
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group tended to have worse cardiac function, larger LVEDD, 
higher NT-proBNP, and less often used angiotensin converting 
enzyme inhibitor/angiotensin receptor blockers (ACEI/ARB) 
(Table 1).
Clinical outcomes 
Mean follow-up period was 4.17 ± 3.16 years, and it was 
completed by 296 patients. There were 53 (17.9%) cases of 
all-cause death, 41 (13.8%) cases of HFH, and four (1.4%) 
cases of heart transplantation. Among deceased patients, 
29 (9.8%) died of HF, sudden death occurred in 12 (4.1%) 
patients, and 12 (4.1%) patients died of non-cardiac causes, 
such as car accident and fatal stroke (Fig. 1).
At the six-month follow-up, a total of 129 patients had 
a decrease of at least one FMR level from the baseline, 
91 (70.5%) were in the SMR group, and 38 (29.5%) were in the 
non-SMR group. Response to CRT was observed in 63 (58.8%) 
patients in the SMR group and 98 (56.9%) patients in the 
non-SMR group. However, neither improvement in FMR nor 
response to CRT were statistically significant in either group.
Survival analysis of primary endpoints
Kaplan-Meier survival analysis was performed to compare the 
survival conditions between the SMR group and the non-SMR 
group (Fig. 2). The results showed that the risk of primary 
Table 1. Baseline characteristics of patients with and without significant mitral regurgitation (SMR)
Variables Overall Non-SMR SMR p
Number of patients 296 172 124
Age [years] 59 ± 11 59 ± 11 58 ± 11 0.784
Male sex 202 (68.2%) 121 (70.3%) 81 (65.3%) 0.359
CRT-D 143 (48.3%) 76 (44.2%) 67 (54%) 0.094
IHD 63 (21.3%) 41 (23.8%) 22 (17.7%) 0.206
AF 43 (14.5%) 23 (13.4%) 20 (16.1%) 0.507
LBBB 251 (84.8%) 143 (83.1%) 108 (87.1%) 0.350
NYHA class:
II 69 (23.3%) 57 (33.1%) 12 (9.7%) < 0.001
III 174 (58.8%) 90 (52.3%) 84 (67.7%) 0.008
IV 50 (16.9%) 23 (13.4%) 27 (21.8%) 0.057
Initial QRS width [ms] 160.76 ± 19.44 159.27 ± 19.25 162.84 ± 19.58 0.119
LVEDD [mm] 70.39 ± 9.40 68.79 ± 9.30 72.60 ± 9.12 0.001
LVESD [mm] 62.43 ± 24.96 60.69 ± 28.35 64.82 ± 19.28 0.308
LVEF [%] 29.02 ± 7.88 30.30 ± 7.77 27.25 ± 7.71 0.001
LVESV [mL] 189.72 ± 65.24 167.43 ± 71.25 194.64 ± 60.37 0.210
NT-proBNP [pg/mL] 1893.72 ± 1555.59 1537.48 ± 1384.11 2382.62 ± 1649.87 < 0.001
ACEI/ARB 231 (78.0%) 147 (85.5%) 84 (67.7%) < 0.001
b-blockers 265 (89.5%) 153 (89.0%) 112 (90.3%) 0.704
Amiodarone 68 (23.0%) 39 (22.7%) 29 (23.4%) 0.886
Spironolactone 274 (92.6%) 162 (94.2%) 112 (90.3%) 0.211 
Data presented as number (percentage) or mean ± standard deviation. NT-proBNP was measured in 223 patients. ACEI — angiotensin converting 
enzyme inhibitor; AF — atrial fibrillation; ARB — angiotensin receptor blockers; CRT-D — cardiac resynchronisation therapy with a defibrillator; 
IHD — ischaemic heart disease; LBBB — left bundle branch block; LVEDD — left ventricular end-diastolic diameter; LVEF — left ventricular ejection 
fraction; LVESD — left ventricular end-systolic diameter; NT-proBNP — N-terminal pro-B-type natriuretic peptide; NYHA — New York Heart  
Association functional classification
Figure 1. Percentage of survivors and deceased patients with 
specified cause of death; HF — heart failure
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endpoints was increased with SMR before CRT implantation 
(log-rank test, p = 0.0172, c2 = 5.678).
Predictors of primary endpoints
In the multivariate Cox proportional hazard regression model, 
SMR (hazard ratio [HR] 1.785, 95% confidence interval [CI] 
1.091–2.920, p = 0.021), IHD (HR 1.628, 95% CI 1.062– 
–2.494, p = 0.025), and the lack of use of spironolactone (HR 
2.044, 95% CI 1.040–4.017, p = 0.038) were independent 
predictors of primary endpoints (Table 2).
Finally, SMR remained an independent predictor of HFH 
(HR 4.622, 95% CI 1.955–10.923, p < 0.001) (Table 3).
DISCUSSION
In our study, the proportion of CRT candidates with FMR was 
78.0%, with the proportion of SMR patients up to 41.8%. We 
demonstrated that SMR constituted a risk factor for long-term 
poor prognosis in patients receiving CRT. The survival analysis 
proved the independent prognostic value of SMR for primary 
endpoints. Specifically, SMR was positively associated with HFH 
rather than HF-related death, sudden death, and response to CRT, 
according to logistic regression analysis. Finally, we also found that 
IHD and the lack of use of spironolactone were positively associ-
ated with primary endpoints after adjusting for multiple factors.
With a high morbidity and mortality, HF has become 
a major health problem in the ageing society, placing a huge 
economic burden on patients. LV dyssynchrony contributes to 
the imbalance of closing force and stretch stress of the mitral 
valve, and results in FMR. Previous studies have shown that 
a quarter of patients with HF demonstrate at least mild FMR, 
and more than 50% demonstrate moderate or severe FMR 
at baseline [2, 5].
Figure 2. Kaplan-Meier plot estimating survival of patients free from primary endpoints according to severity of functional mitral 
regurgitation; SMR — significant mitral regurgitation
Table 2. Predictors of primary endpoints in uni- and multivariate Cox proportional hazards models
Variable Univariate model HR (95% CI) p Multivariate model HR (95% CI) p
SMR 1.602 (1.083–2.371) 0.019 1.785 (1.091– 2.920) 0.021
IHD 1.628 (1.062–2.494) 0.025 1.682 (1.062–2.494) 0.025
AF 1.787 (1.083–2.948) 0.033 – –
CRT-D 1.033 (0.696–1.534) 0.026 – –
NYHA class IV 1.960 (1.268–3.029) 0.002 – –
NT-proBNP 1.000 (1.000–1.000) 0.031 – –
LVEDD 1.015 (0.995–1.036) 0.140
LVESD 1.003 (0.996–1.009) 0.430
ACEI/ARB 0.625 (0.404–0.967) 0.035 – –
b-blockers 0.647 (0.374–1.119) 0.647
Lack of spironolactone 2.368 (1.387–4.042) 0.002 2.044 (1.040–4.017) 0.038
Only variables with p < 0.05 in univariate analyses were included in multivariate model; CI — confidence interval; HR — hazard ratio;  
SMR — significant mitral regurgitation; other abbreviations — see Table 1
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The occurrence of FMR was generally regarded as a pow-
erful predictor for poor prognosis of systolic HF patients. As 
for CRT candidates, some previous studies have shown that 
preoperative FMR indicates a weak response and worse 
long-term clinical outcome in patients with CRT [17], while 
other studies indicated that the baseline level of FMR was not 
associated with long-term clinical prognosis [18, 19]. This may 
be due to the relatively short follow-up period and the small 
number of samples with different FMR group criteria in those 
studies. Our study concentrated on SMR (jet area/left atrial 
area > 30%) during a follow-up of 4.17 ± 3.16 years. We 
found that when comparing the relationship between SMR 
and different outcomes, SMR was strongly associated with 
HFH, indicating that the level of FMR may be more related 
to HF symptoms rather than mortality and CRT response. 
In our population, the proportion of non-ischaemic HF 
patients was relatively large compared to the other stud-
ies. In the study of Yamamoto et al. [20], the proportion of 
IHD patients is 22.2% (26/117). A similar percentage (18%) 
of IHD patients was enrolled in our study. Non-ischaemic 
aetiology was more frequent in patients with improving FMR 
and better prognosis after CRT. This observation was consistent 
with previous findings [21, 22]. People with IHD had a lower 
echocardiographic response to CRT, and it may have resulted 
from the presence of scarring at the site of the papillary muscle 
or from progressive regional loss of viable myocardium due 
to ischaemia, both of which may have limited the efficacy of 
CRT [23, 24].
For a single-centre, observational study, the number 
of patients was relatively small. Results from the current 
study should be confirmed in further, large-scale clinical tri-
als. Moreover, the method of FMR quantification based on 
the jet area/left atrial area ratio was only a semi-quantitative 
method compared with integration of various echocardio-
graphic measures of FMR severity [25]. Moreover, because 
it was a non-controlled study, no conclusions can be made 
regarding the possible benefits of CRT. However, to ensure the 
effects of CRT, strict heart rate control with medication was 
performed and a percentage of biventricular pacing > 90% 
was achieved in all subjects during follow-up.
In conclusion, SMR before CRT implantation was strongly 
related to long-term poor prognosis in HF patients. SMR 
was positively associated with HF hospitalisation rather than 
mortality and CRT response. 
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